New cancer drug combo tested in advanced tumors – early results show promise
NCT ID NCT06580938
First seen Apr 05, 2026 · Last updated Apr 28, 2026 · Updated 5 times
Summary
This early-stage study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in 4 adults with advanced solid tumors like lung, bladder, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists Sarasota Drug Development Unit
Sarasota, Florida, 34232, United States
-
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
-
Highlands Oncology Group
Rogers, Arkansas, 72758, United States
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
Presbyterian/St. Lukes Medical Center
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute- Pharmacy
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.